Trodelvy

Active Ingredient(s): Sacituzumab Govitecan-hziy
FDA Approved: * April 22, 2020
Pharm Company: * IMMUNOMEDICS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Trodelvy Overview

Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate for the treatment of adults with triple-negative breast cancer (TNBC) that has spread to other parts of the body and have received at least two prior therapies.[1][2] The most common side effects are nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal ...

Read more Trodelvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sacituzumab_govitecan

Recent Trodelvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sacituzumab Govitecan-hziy
  • Injection: 180mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trodelvy: (1 result)

Sorted by National Drug Code
  • 55135-132 Trodelvy 180 mg Intravenous Powder, for Solution by Immunomedics, Inc.

Other drugs which contain Sacituzumab Govitecan-hziy or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 November 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA